SEARCH FOR PREDICTORS OF TARGET TREATMENT DISCONTINUATION DUE TO SIDE EFFECTS IN RHEUMATOID ARTHRITIS PATIENTS. DATA FROM MOSCOW ARTHRITIS REGISTRY

E. N. Koltsova; Кольцова Е. Н.; G. V. Lukina; Лукина Г. В.; E. I. Schmidt; Шмидт Е. И.; E. V. Zhilyaev; Жиляев Е. В.

doi:10.31857/S102872210006612-8

SEARCH FOR PREDICTORS OF TARGET TREATMENT DISCONTINUATION DUE TO SIDE EFFECTS IN RHEUMATOID ARTHRITIS PATIENTS. DATA FROM MOSCOW ARTHRITIS REGISTRY

Authors: Koltsova E.N.¹^,2, Lukina G.V.²^,3, Schmidt E.I.⁴, Zhilyaev E.V.⁵^,6
Affiliations:
1. Research Institute of the Organization of health and healthcare management
2. Moscow Clinical Scientific Center
3. V. A. Nasonova Research Institute of Rheumatology
4. City Clinical Hospital 1 named after N. I. Pirogov
5. Russian Medical Academy of continuing professional education
6. CJSC «European Medical Center»
Issue: Vol 22, No 2-1 (2019)
Pages: 314-316
Section: ORIGINAL ARTICLES
URL: https://rusimmun.ru/jour/article/view/133
DOI: https://doi.org/10.31857/S102872210006612-8
ID: 133

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The aim: to detect predictors of target drug withdrawal due to adverse events among patients with rheumatoid arthritis. Materials and methods: The study includes patients with rheumatoid arthritis from the Moscow Arthritis Registry (MAR), receiving treatment with biologics or tofacitinib. Results: Analysis includes 1230 treatment events in 696 patients. The mean age was 54,6±12,9 years. The mean observation time – 5.3 years. There were 146 cases of therapy discontinuation due to adverse events. Рresence of rheumatoid nodules, higher doses of glucocorticoids, lower doses of methotrexate were independent signifi cant predictors of increased risk of target treatment withdrawal due to side eff ects. Used target drug also showed independent signifi cant correlation with this risk. Conclusion: The use of full doses of methotrexate, reduce the use of glucocorticoids can be considered as a measure to prevent the development of adverse events in patients treated with target therapy.